整理 | GLP1减重宝典内容团队 司美格鲁肽、替尔泊肽等类似的减肥药已成为世界上最受欢迎的药物之一。但也有大批人停止服用它们。根据一项行业分析， 2021 年，美国约有三分之二开始服用此类药物（称为 GLP-1 激动剂）的人在一年内停止使用它们。 研究显示，当人们停止服用 GLP-1 激动剂时，一些人恢复了一部分体重。 身体自然会试图保持自己的体重点，肥胖专家 Arya Sharma 把这种拉力比作绷紧的橡皮筋。 如果你服用药物来改变你的生理机能，"橡皮筋的张力就会小很多"，他解释道。"但是当我停止服用药物时，这种张力就会再次出现"， Sharma说，他现居柏林，为几家对肥胖感兴趣的公司提供兼职咨询服务。 研究人员和临床医生通常将 GLP-1 激动剂视为终身治疗。 但无数因素可能会 迫使 人们停止服药。人们可能会失去支付昂贵药物的手 段、经历严重的副作用、受到持续短缺的影响或被提供有限期限的处方。 随着肥胖人数不断增加——世界卫生组织估计，目前肥胖人数超过 10 亿，占世界人口的八分之一——研究人员一直在回答一些关键问 题： ▍ 当人们停止服用司美格鲁肽后，体重和健康状况会发生什么变化？ Ozempic 和 ...

Group 1 - Novo Nordisk's Wegovy and Eli Lilly's Mounjaro saw sales in India double in July compared to June, indicating strong demand for these obesity treatments [1] - Wegovy's sales reached 5,000 units with a revenue of 70 million INR (approximately 797,000 USD), while Mounjaro's sales hit 157,000 units with a revenue of 470 million INR [1] - Novo Nordisk's Q2 sales were 76.857 billion DKK, a 13% year-over-year increase, with a net profit of 26.503 billion DKK, up 32% [2] Group 2 - Eli Lilly reported Q2 revenue of 15.6 billion USD, a year-over-year increase of approximately 38%, but faced challenges with its oral weight loss drug underperforming expectations [2] - Novo Nordisk is advancing its research on Amycretin for weight management and has initiated the REDEFINE11 study to explore CagriSema's potential [2] - As of the latest trading, Novo Nordisk's stock rose by 8% in pre-market, while Eli Lilly's stock fell by 7.8% [3]

Core Viewpoint - Semaglutide, developed by Novo Nordisk, has significantly impacted the weight loss market with over $7.8 billion in global sales in Q1 this year, approved for treating type 2 diabetes and obesity [2] - Tirzepatide, developed by Eli Lilly, is rapidly gaining ground, showing superior weight loss results compared to Semaglutide in recent studies [4][5] Group 1: Clinical Trial Results - In the SURMOUNT-5 trial, Tirzepatide led to an average weight loss of 20.2% (approximately 22.8 kg) over 72 weeks, with 31.6% of participants losing 25% or more of their body weight [5] - The REDEFINE 1 trial showed that the combination of Cagrilintide and Semaglutide (CagriSema) resulted in an average weight loss of 20.4% (approximately 26.6 kg) over 68 weeks, outperforming both Semaglutide and Cagrilintide alone [8] - In the REDEFINE 2 trial, CagriSema achieved an average weight loss of 13.7% in type 2 diabetes patients, significantly higher than the 3.4% in the placebo group [10][13] Group 2: Safety and Side Effects - CagriSema treatment was associated with a higher incidence of gastrointestinal adverse events (79.6%) compared to the placebo group (39.9%), though most symptoms were mild to moderate [8][13] - In the REDEFINE 2 trial, 72.5% of CagriSema participants reported gastrointestinal side effects, again higher than the 34.4% in the placebo group [13] Group 3: Market Outlook - The combination of Semaglutide and Cagrilintide shows potential to become a significant player in the obesity treatment market, alongside Semaglutide and Tirzepatide [14] - The results from recent clinical trials suggest that CagriSema may redefine the competitive landscape of weight loss medications, particularly in both diabetic and non-diabetic populations [14]